| Attributes | Values |
|---|
| rdf:type
| |
| Description
| - Akutní promyelocytární leukemie (APL) je vzácnou formou akutní myeloidní leukemie, která představuje přibližně 5 - 10 % všech akutních myeloidních leukemií u dospělých. Před terapeutickým použitím dnes jediného u nás klinicky aplikovaného léčiva - kyselinou all-trans retinovou (ATRA) byla prognosticky nejhorším typem akutní leukemie. Ve farmakologických koncentracích je ATRA nejaktivnější dostupnou cytodiferenciační látkou a zároveň má silný antiproliferativní a apoptotický potenciál. ATRA překonává blokádu diferenciace pozorovanou u tohoto typu leukemie a to bez cytotoxického efektu typického pro chemoterapeutika používaná v onkologii. Možnost dosáhnout klinické remise u APL pacientů použitím látky s novým farmakologickým mechanismem vzbudila značné nadšení a naděje pro využití i u dalších typů leukemie a solidních nádorů. Tyto naděje podnítily snahu vyvinout syntetické molekuly (retinoidy) s výhodnějším terapeutickým účinkem a vyšší receptorovou selektivitou, ale také zájem o kombinovanou terapii za (cs)
- Enhancing the pharmacologic activity of all-trans retinoic acid (ATRA) is potentially useful in the management of acute promyelocytic leukemia (APL) and other types of myeloid leukemia. In this report, we identify a novel class of experimental agents selectively potentiating the cytodifferentiating activity of ATRA and synthetic retinoic acid receptor alpha agonists in APL and other myeloid leukemia cell lines. These agents have a bis-indolic structure (BISINDS), and ST1346 is the prototypical compound of the series. Gene-profiling experiments and determination of the level of expression of myeloid-associated markers indicate that ST1346 stimulates many aspects of the granulocytic maturation process set in motion by ATRA. Stimulation of the cytodifferentiating activity of ATRA by ST1346 enhances the efficacy of the retinoid in vivo, as demonstrated in the APL model of the severe combined immunodeficiency (SCID) mouse receiving transplants of NB4 cells. Although the molecular mechanisms underlying the
- Enhancing the pharmacologic activity of all-trans retinoic acid (ATRA) is potentially useful in the management of acute promyelocytic leukemia (APL) and other types of myeloid leukemia. In this report, we identify a novel class of experimental agents selectively potentiating the cytodifferentiating activity of ATRA and synthetic retinoic acid receptor alpha agonists in APL and other myeloid leukemia cell lines. These agents have a bis-indolic structure (BISINDS), and ST1346 is the prototypical compound of the series. Gene-profiling experiments and determination of the level of expression of myeloid-associated markers indicate that ST1346 stimulates many aspects of the granulocytic maturation process set in motion by ATRA. Stimulation of the cytodifferentiating activity of ATRA by ST1346 enhances the efficacy of the retinoid in vivo, as demonstrated in the APL model of the severe combined immunodeficiency (SCID) mouse receiving transplants of NB4 cells. Although the molecular mechanisms underlying the (en)
|
| Title
| - Bis-indoly, nová skupina látek zvyšujících cytodiferenciační vlastnosti retinoidů v léčbě buněk myeloidní leukemie. (cs)
- Bis-indols: a novel class of molecules enhancing the cytodifferentiating properties of retinoids in myeloid leukemia cells.
- Bis-indols: a novel class of molecules enhancing the cytodifferentiating properties of retinoids in myeloid leukemia cells. (en)
|
| skos:prefLabel
| - Bis-indoly, nová skupina látek zvyšujících cytodiferenciační vlastnosti retinoidů v léčbě buněk myeloidní leukemie. (cs)
- Bis-indols: a novel class of molecules enhancing the cytodifferentiating properties of retinoids in myeloid leukemia cells.
- Bis-indols: a novel class of molecules enhancing the cytodifferentiating properties of retinoids in myeloid leukemia cells. (en)
|
| skos:notation
| - RIV/62157124:16370/02:00000003!RIV06-MSM-16370___
|
| http://linked.open.../vavai/riv/strany
| |
| http://linked.open...avai/riv/aktivita
| |
| http://linked.open...avai/riv/aktivity
| |
| http://linked.open...iv/cisloPeriodika
| |
| http://linked.open...vai/riv/dodaniDat
| |
| http://linked.open...aciTvurceVysledku
| |
| http://linked.open.../riv/druhVysledku
| |
| http://linked.open...iv/duvernostUdaju
| |
| http://linked.open...titaPredkladatele
| |
| http://linked.open...dnocenehoVysledku
| |
| http://linked.open...ai/riv/idVysledku
| - RIV/62157124:16370/02:00000003
|
| http://linked.open...riv/jazykVysledku
| |
| http://linked.open.../riv/klicovaSlova
| |
| http://linked.open.../riv/klicoveSlovo
| |
| http://linked.open...odStatuVydavatele
| |
| http://linked.open...ontrolniKodProRIV
| |
| http://linked.open...i/riv/nazevZdroje
| |
| http://linked.open...in/vavai/riv/obor
| |
| http://linked.open...ichTvurcuVysledku
| |
| http://linked.open...cetTvurcuVysledku
| |
| http://linked.open...UplatneniVysledku
| |
| http://linked.open...v/svazekPeriodika
| |
| http://linked.open...iv/tvurceVysledku
| - Kollár, Peter
- Garattini, Enrico
- Rambaldi, Alessandro
- Terao, Mineko
- Carminati, Paolo
- Devoto, Antonio
- Ferrara, Fabiana
- Gianní, Maurizio
- Giordano, Vincenzo
- Kalac, Yesim
- Marzi, Mauro
- Moretti, Giampiero
- Penco, Sergio
- Pisano, Claudio
- Rinaldi, Alessandra
- Tancredi, Richard
- Tinti, Ornella
- Vesci, Loredana
|
| http://linked.open...n/vavai/riv/zamer
| |
| issn
| |
| number of pages
| |
| http://localhost/t...ganizacniJednotka
| |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)